• AstraZeneca published a transcript from its “Meet AZN Management: ERS 2026” investor call on Sept. 8, 2026, attended by investors, analysts, and external expert Frank C. Sciurba.
• Management highlighted Phase III COPD data for IL-33 antibody tozorakimab from replicate OBERON and TITANIA studies added to standard inhaled care.
• Primary endpoint met in former smokers: exacerbation rate ratios 0.71 (p=0.002) in OBERON, 0.66 (p<0.001) in TITANIA.
• Key secondary endpoint met in the overall population: rate ratios 0.70 in OBERON, 0.71 in TITANIA, each p<0.001.
• Management cited Priority Review in the US with a Q1 2027 PDUFA date, positioning tozorakimab as a potential $5 billion-plus asset.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on September 08, 2026, and is solely responsible for the information contained therein.